Background : Nicotine is a substance that stimulate addiction, it is makes the people difficulty to quit. Nicotine will stimulate of releasing neurotransmitter in a brain and makes the interaction between nicotinic acethilcholine receptors (nAChRs) on mesolimbic system in a brain. With - chronic exposure, neuroadaptation to some of athe effects of nicotine developsa Increasing of neurotransmitter will activated of on 7 n.AChRs binding sites. 7 nAChRs have contribution for addiction. When abstinensi the subject will appears nicotine withdrawal syndrome such as depression, anxiety, and body weight gain. Nicotine withdrawal will stimulate to use nicotine again. Delphinium spp. is alkaloid with methyllcyaconitine (MEA) which competitive antagonist to inhibit a7-, a6-, dan a3 nAChRs. It is potential for treatment of nicotine dependence. Research Methodology: quasi experiment dengan pre post control group design. Gl(negative control), 02 (positive control). G2, 03, 04 induced by nicotine. The doses are 0,38 jig/mI in 8th and 9th days, 0,61 .ig/ml in 10th and 11th days, 0,96 .tgIm1 in 12th and 13th days, 1,54 g/m1 in 14th and 15th days, 3,84 g /ml in 16th days, 6,14 jig /ml in 17th, 9,60 jig /ml in 18th, 15 jig /ml in 19th days, 36 jig /ml in 20th until 22th. 23” days measurifig nicotine withdrawal. 2325th days treatment by Delphinium grandifiorum peroral (33 (3mg/kg), 04 (6mg/kg). 26th days measuring nicotine withdrawal syndrome. Result: Ethanolic extract Delphinium grandiflorum peroral doses 3 mg/kg and 6 mg/kg cannot increasing body weight to G3 and G4.It is means significant. Ethanolic extract Delphinium grandiflorum peroral doses 3 mg/kg and 6 mg/kg cannotdecreasing anxiety. It is means not significant.